

6 **Abstract**

7 **Background:** Experts suggests formulary alerts at medication order entry is the most effective
8 form of clinical decision support to automating formulary management.

9 **Objective:** Our objectives was to quantifying the frequency of inappropriate NFM alert
10 overrides in the inpatient setting and provide insight on how to better design formulary alerts
11 for automated formulary management.

12 **Methods:** The NFM alert overrides of 206 highest costing and most utilized NFM from 2012
13 were randomly selected for appropriateness evaluation. Using an empirically developed NFM
14 alert appropriateness algorithm, appropriateness of NFM alert overrides were assess by two
15 pharmacist via in-depth chart review. Appropriateness agreement of NFM alert overrides was
16 assessed with a Cohen's kappa. Exploratory analysis assessed which types of NFMs were most
17 likely to be inappropriately overridden, which type of override reasons was disproportionately
18 associated with inappropriate alert overrides, and what reasons explained why a NFM alert was
19 overridden inappropriate.

20 **Results:** Approximately 17.5% (n=36/206) of NFM alerts are inappropriately overridden. Non-
21 oral NFMs alerts are more likely to be inappropriately overridden compared to oral NFMs.
22 Alerts overridden with 'blank' reasons were more likely to be inappropriate. The failure to first
23 trial a formulary alternative is the most common reason for a NFM alert overridden
24 inappropriately.

25 **Conclusion:** Conservatively about one in five NFM alert overrides are overridden
26 inappropriately. Mandating an override reason for each NFM alert override and adding a list of

- 27 formulary alternatives to each NFM alert may decrease the frequency of inappropriate NFM
- 28 alert overrides.

29 **Introduction**

30 A hospital formulary is a list of medications agreed upon by hospital healthcare providers
31 for the care of admitted patients.¹ Medications on this list are often the cost-effective option
32 compared to their non-formulary alternatives, also termed non-formulary medications (NFM).
33 Typically, NFMs are not stocked and require special order entry and procurement procedures
34 by the prescriber and pharmacy prior to use. These special order entry and procurement
35 procedures increases labor cost (\$15.94 to \$23.34)²⁻⁴ and can substantially delay NFM initiation
36 (10.6 hours).³ NFMs are also error prone, because they are unfamiliar to hospital staff may be
37 misinterpret for the more familiar formulary medications.⁵⁻⁸

38 However, the need for hospitals to provide NFMs is inevitable. There are times when
39 admitted patients are stabilized on a pre-admission, chronic NFM and substitution with a
40 formulary alternative can induce harm. Experts suggests formulary CDS, at medication order
41 entry, in the form of a pop-up alert containing a list of formulary alternatives is the most
42 effective design in balancing the need of NFMs while limiting the ill-effects of formulary non-
43 compliance.⁹ Empiric verification of this suggestion is limited. Analogous evidence can be drawn
44 from the more commonly used computerized alerts (drug-allergy, drug-drug interactions, drug-
45 disease contraindication, etc.), where studies have shown these alerts improve prescribing
46 behaviors, reduce prescribing errors, impact clinical outcomes, and decrease medication cost.¹⁰
47 However, these benefits have often been challenged by the high frequency of alert overrides
48 (49-96%).¹¹ Therefore, we are unsure if the aforementioned alerts benefits can be generalized
49 to formulary alerts.

50 To our knowledge there are no studies evaluating the appropriateness of NFM alert
51 overrides. Our experience suggests this may be attributed to the resource-intensive task of
52 creating appropriateness criteria for each NFM. In our previous study, we empirically developed
53 a ‘general’ appropriateness algorithm that institutions could adapted to evaluate the
54 appropriateness of their institution specific NFM alert overrides. We adapted this general
55 algorithm to our institution’s NFM use policy and criteria and evaluated the appropriateness of
56 a random sample of NFM alert overrides.

57 **Methods**

58 *Setting*

59 Brigham and Women’s Hospital (BWH) is a 793-bed academic medical center located in
60 Boston, MA and admits approximately 46,000 patients annually for a full range of inpatient
61 services, with the exception of pediatrics. Medications available for patient care are governed
62 by BWH’s formulary. Inpatient medications are ordered through an in-housed developed
63 computerized provider order entry (CPOE) system inside Brigham Integrated Computer System
64 (BICS). Full details of BICS and the CPOE system are described elsewhere.¹² Formulary alerts
65 embedded in the CPOE system are used to automate formulary management. Upon order entry
66 of a NFM, prescribers are informed of its non-formulary status with three types of pop-up
67 alerts: 1) a ‘soft stop’ requesting the input of a free-texted override reasons, explaining the
68 rationale of formulary deviation, 2) an ‘intermediate stop’ requesting an override reason and
69 the identifying the specialist physician who approved the NFM for use, and 3) a ‘hard stop’

70 stating the NFM is not available for use and prompting the prescriber to order the preferred
71 formulary alternative (**Figure 1 and 2**).




Figure 1: Non-formulary medication alerts

The dashed line represents the hard stop directing the prescriber to order a preferred NFM alternative. In this example Quetiapine XR cannot be ordered, but the hard stop directs the prescriber to order Quetiapine which is also NFM. The soft stop directs the provider to enter a reason why NFM is needed.

A.

NON-FORMULARY MEDICATION REQUEST

QUETIAPINE PO

R


This is a Non-Formulary drug.
Please enter the reason(s) that this drug is needed:

D

I
P
2

OK CANCEL

Enter up to 4 lines of text.
Press Enter on a blank line to end, Esc to cancel



B.

MEDICATION ORDER	
<input checked="" type="checkbox"/> New <input type="checkbox"/> Change <input type="checkbox"/> D/C	Medication Name [ERTAPENEM SODIUM]
	Route [IV] [] Soundex PAML Builder
ERTAPENEM ALL ROUTES	P&T NOTICE
<p>Please note! You have chosen a restricted antimicrobial which requires Infectious Disease Approval. If you have ID approval please enter the name of the approver when prompted. If you don't have ID approval, please page the Antibiotic Approval pager #22927 8am to 8pm to discuss. The Antibiotic Approval pager is unavailable 8pm to 8am pharmacy will dispense a 12-hr supply after review. Please page Antibiotic Approval pager #22927 after 8am tomorrow to discuss.</p>	
<input type="button" value="order Ertapenem sodium"/>	<input type="button" value="Cancel order"/>

C.

MEDICATION ORDER

(*) New Medication Name [RANITIDINE HCL]

() ChangeE

() D/C Route [IV] [] Soundex PAML Builder

() Change Route

<breastfeedUNK>

D Dose: []

Ranitidine (Zantac) Intervention

The Pharmacy & Therapeutics Committee has determined the H2 antagonist class to be therapeutically interchangeable. Peppid (famotidine) is the H2 antagonist of choice at BWH. Please order famotidine. If you have any questions please contact the pharmacy at ext. 2-7153.

cancel order

Figure 2: Non-formulary pop-up alerts

A) Soft stop, B) Intermediate stop, and C) Hard stop

72 Study Design and Sampling of NFM alert overrides

73 The present study was an observational study of NFM alerts overridden from January 1st
74 to December 31st, 2012. These overrides and their relevant data elements were extracted from
75 BICS and loaded into a Microsoft Access Database (Microsoft Corp, Redmond, WA). Relevant
76 data elements included patient's medical record number, patient name, admission date,
77 discharge date, NFM order entry date, NFM order entry time, medication unique identifier,
78 generic medication name, route, dosage, dosing frequency, estimated number of doses
79 required, , prescriber name, prescriber unique identifier, and the free-texted NFM alert
80 override reason.

81 We limited our sample of NFM alert overrides to only original overrides and excluded
82 those that were the result of medication dose, direction, or frequency changes. The latter
83 overrides' rational for formulary deviation were often the same as the original and including
84 them into our evaluation would duplicate alerts. Further, at BWH there are two sources of non-
85 formulary designation, one in BICS and the other in an online formulary dictionary. Our internal
86 study found inconsistencies in these two sources. To ensure our evaluation included only true
87 NFMs, we further limited our overrides sample to medications listed as non-formulary in both
88 sources.

89 Total medication cost, composed of procurement and medication cost from 2009 to
90 2012, were computed for each NFM. The average procurement cost of providing a NFM over
91 formulary alternatives was estimated to be \$20.07 per order.² This estimate was used to
92 convert the number of NFM orders to a monetary value. Medication costs were estimated from
93 a BWH's medication wholesaler account during the first quarter of 2014. NFMs were ranked

94 from highest to lowest total cost and twenty alert overrides were randomly selected from the
95 top 11 NFM alert override appropriateness evaluation. **Figure 3** describes our NFM alert
96 override sampling scheme.




Figure 3: NFM alert override random selection
^ψTop 11 most approved and highest costing NFM alert overrides
^γIn 2012 there were only six alert overrides for liposomal doxorubicin


97

98 NFM alert override appropriateness criteria

99 Previously, we empirically developed a general NFM alert override appropriateness
100 algorithm from free-texted NFM alert override reasons. Full details of the methodology and
101 performance of the algorithm can be found elsewhere (*citation AJHP Study*). In brief, a NFM
102 alert override reason categorization scheme was created from a random sample of 5,000
103 overrides according to keywords, context, and value explaining the rationale for formulary
104 deviation. A 30 question appropriateness algorithm was initially developed from these override
105 reason categories and presented to an interdisciplinary team of healthcare providers to
106 evaluate clinical creditability and for feedback. BWH inpatient pharmacist and pharmacy
107 administrators were also consulted on the NFM ordering process and the algorithm was
108 simplified to an eight question general appropriateness algorithm (**Figure 4**). Available BWH
109 medication monographs, treatment guidelines and medication administration guidelines of the
110 top 11 NFMs were ascertained from the BWH Pharmacy intranet website and incorporated into
111 the general algorithm to create insitution specific NFM alert override algorithms.

112

Figure 4: General_NFM alert override appropriateness algorithm



114 Chart review and appropriateness evaluation

115 An appropriateness evaluation interface was created in a Microsoft Access Form, where
116 all aforementioned relevant data elements were displayed. This was an attempt to mimic
117 formulary management at the at the point of care. All inpatient notes in “portable document
118 format” (PDF) corresponding to the hospitalization when the NFM alert was overridden was
119 downloaded from BICS and a hyperlink to this document was created in the Microsoft Access
120 Form to facilitate reviewer access. All medication orders, labs, and medication administration
121 logs during hospitalization were available through BICS. Outpatient medication records were
122 available through BWH’s ambulatory care electronic medical record, Longitudinal Medical
123 Record (LMR).

124 Two pharmacists (QLH and MGA) assess the appropriateness of each NFM alert override
125 according to the institution specific NFM appropriateness algorithms via in-depth chart.
126 Generally, pharmacists first reviewed the override reason explaining the formulary deviation
127 and identified ‘preliminary’ formulary alternatives to the NFM. Second, the pharmacists
128 ensured that the NFM was not contraindicated or potentially induced any significant harm to
129 the patient according to the information found in the inpatient chart (i.e. chief complaint of
130 admission, medical history, allergies, or drug interactions). If the NFM posed any threat of
131 harming the patient, the NFM alert override was considered inappropriate. The reviewers also
132 reviewed medication orders and medication administration logs for evidence of trialing
133 formulary alternatives prior to the NFM alert override. The NFM alert override was considered
134 appropriate if a formulary alternative was first tried or documentation in the inpatient notes
135 reasonably explained why a formulary alternative was not an option, otherwise the NFM alert

136 override was inappropriate. Disagreements between pharmacists were resolved by discussion
137 with a third reviewer (DLS).

138 In our previous study, approximately one-half of all NFM alerts overrides were justified
139 with entered blanks and marginal value reasons (i.e. patient needs medication, patient
140 requires, attending prefers, etc.) (*AJHP citation*). It is possible that these overrides are
141 appropriate, but justification was poorly documented. For example, there could be occasions
142 where specialist were consulted or formulary alternatives were thoroughly evaluated and
143 found to induced drug interactions, but the prescriber passively entered a 'blank' or marginal
144 value reason in the NFM alert override interface. Thus, 'blank' and marginal value reasons were
145 deemed inappropriate unless an appropriate justification (specialist consult, pharmacological
146 interaction, active disease that required the medication etc) for the NFM was discovered during
147 chart review.

148 Our previous study, we also found a significant number of NFM alert overrides were
149 justified with syntax variants of the NFM being a pre-admission or home medication. In these
150 cases the NFM alert override was considered appropriate only if the NFM was found active in
151 the LMR's electronic medication list during the dates of hospitalization. For NFM's justified by a
152 'disease or condition' reason, the literature was searched to ensure minimal supporting
153 evidence existed (at least a case-report) for the NFM's proposed indication. Any level of clinical
154 evidence found concluding effectiveness and citation of the 'disease or condition' in the
155 inpatient notes prompted these overrides to be deemed as appropriate. Remaining potential
156 reasons included specialist or pharmacist recommendation, therapeutic failure or intolerance
157 to NFM's, pharmacological reasons, end of life care, and drug shortages. NFM alerts overridden

158 with these reasons were appropriate as long as there was documented evidence in the
159 inpatient notes. For example, olanzapine was often justified with ‘per psych recommendation,’
160 this NFM alert override would be considered appropriate if a psychiatrist consult
161 recommending the medication was existed in the inpatient notes prior the NFM being ordered.

162 Outcomes and objectives

163 Our primary objective was to quantify the frequency of NFM alerts overridden
164 inappropriately, computed as the ratio of NFM alerts overridden not according to our
165 appropriateness algorithms over the total number of overrides in our sample. Secondary
166 objectives included identifying (1) which types of NFMs (oral and non-oral) were most likely to
167 be inappropriately overridden, (2) which category of NFM alert override reasons
168 disproportionately represent inappropriate NFM alert overrides, and (3) reasons explaining why
169 the NFM alert override was inappropriate. ***A post-hoc analysis was report the frequency of
170 override reason given in NFM alert pop-up not congruent to the formulary deviation reason
171 documented in the inpatient notes; we term these discrepancies as discordant override
172 reasons.***

173 Statistical Analysis

174 Counts and frequencies were used to summarize the number of inappropriate overrides
175 according to our NFM alert override reason categorization scheme. Agreement in the
176 inappropriateness of NFM alert overrides between the two pharmacists was evaluated with a
177 Cohen’s kappa. Fischer’s exact test was used to compare the distribution of inappropriate NFM

178 alert overrides among oral and non-oral NFMs. A p-value of less than 0.05 was considered to be
179 statistically significant.

180 A Fischer's exact test was also first used to determine if inappropriate NFM alert
181 overrides were disproportionately distributed among the override reasons categories. ***If the***
182 ***exact test was found to be statistical significant (p-value < 0.05), the frequency of***
183 ***inappropriate overrides in each override reason category was compared to the frequency of***
184 ***the override reasons using a student t-test. A Bonferroni correction was applied to the student***
185 ***t-test to adjust for multiple testing.*** All statistical analyses were conducted using SAS software
186 (version 9.4 SAS Institute, Cary, NC). This study was approved by the Partners Human Research
187 Committee.

Table 1

Top 11 Most Approved and Highest Costing NFM	Number of NFM Alert Overrides	Inappropriate Alert Overrides	Frequency of Inappropriate Alert Override	Percentage of Total Inappropriate Alert Overrides
Oral non-formulary medications (n=80, 38.8%)				
Aprepitant (PO)	20	0	0.0%	13.9%
Olanzapine (PO)	20	0	0.0%	
Olanzapine ODT (PO)	20	1	5.0%	
Quetiapine (PO)	20	4	20.0%	
Non-oral non-formulary medications (n= 126, 61.2%)				
Dornase Alfa (Neb)	20	4	20.0%	86.1%
Liposomal Doxorubicin (IV)	6	0	0.0%	
Metronidazole 1% (Cream)	20	6	30.0%	
Mometasone Furoate (Inhaler)	20	4	20.0%	
Ranitidine (IV)	20	16	80.0%	
Rasburicase (IV)	20	0	0.0%	
Scopolamine (Patch)	20	1	5.0%	
Total	206	36	17.5%	

189
190 In 2012, 71,145 NFM alerts were overridden, of which 59,102 were original alert
191 overrides for 45,352 hospitalizations. Thus, about 1.3 original NFM alerts were overridden with
192 each hospitalization. The top 11 most approved and highest costing NFM can be found in
193 **Table 1**. Four NFM were oral medications, of which three were atypical antipsychotics. The
194 remaining seven included three intravenous medications, two inhalants, and two topicals. The
195 random selection scheme selected 206 NFM alerts overrides from these medications (there
196 were only six liposomal doxorubicin orders in 2012), which were prescribed by 174 distinct
197 health care providers: 150 physicians, 21 physician-assistants, and three pharmacists.

198 According to the appropriateness algorithms, the two pharmacists found 36 (17.5%)
199 NFM alerts inappropriately overridden (**Table 1**). Agreement between reviewers was high,
200 $\kappa=0.97$ (95% CI: 0.92 – 1.00). Inappropriate alert overrides were disproportionately nested in
201 non-oral NFMs ($p=0.007$), where 86.1% ($n=31$) of inappropriate alert overrides were from non-
202 oral NFMs, while they constituted only 61.2% of the alert override sample (**Table 1**).

Table 2: Non-Formulary Medication Alert Override Appropriateness Evaluation

Initiate Non-Formulary Override Reason Classification	Total Number (Percentage of Total)	Final Appropriateness Evaluation		
		Appropriate	Inappropriate (Percentage of Total)	P-Value ¹
Blank	51 (24.8%)	31	20 (55.6%)	0.0001
Disease or Condition Listed	64 (31.1%)	60	4 (11.1%)	0.0004
Home or Pre-Admission Medication	38 (18.4%)	33	5 (13.9%)	0.4401
Marginal Value for NF Decision:	30 (14.6%)	26	4 (11.1%)	0.5204
<i>Acknowledge NF status</i>	2 (1%)	2	0 (0%)	
<i>Content Free</i>	1 (0.5%)	1	0 (0%)	
<i>MD/Attending/Team Request, Prefers NF Medication</i>	11 (5.3%)	8	3 (8.3%)	
<i>MisCommunication: Medication use direction</i>	3 (1.5%)	3	0 (0%)	
<i>Others</i>	2 (1%)	2	0 (0%)	
<i>Patient Preference/Request</i>	2 (1%)	2	0 (0%)	
<i>Reason Listed "Appropriate, Effective, Indicated, Medical Necessity, No Alternative"</i>	1 (0.5%)	1	0 (0%)	
<i>Reason Listed "Need*/Requir* OR Patient Need*/Require*"</i>	8 (3.9%)	7	1 (2.8%)	
Pharmacological Reason:	4 (1.9%)	3	1 (2.8%)	0.6908
<i>Contraindication</i>	1 (0.5%)	1	0 (0%)	
<i>Drug Route Conflict</i>	1 (0.5%)	0	1 (2.8%)	
<i>Others</i>	2 (1%)	2	0 (0%)	
Specialist Recommendation	10 (4.9%)	9	1 (2.8%)	0.4442
Therapeutic Failure / Intolerant to formulary alternatives:	9 (4.4%)	8	1 (2.8%)	0.6092
<i>Medication Listed</i>	6 (2.9%)	6	0 (0%)	
<i>Unspecified or Medication Not Listed</i>	3 (1.5%)	2	1 (2.8%)	

Total	206	170	36	
--------------	------------	------------	-----------	--

¹*P-values less than 0.007 (=0.05/7) were considered statistically significant, after application of a Bonferroni correction.*

203

204 There were 117 unique override reasons in the 206 NFM alert override sample. These
205 reasons were categorized into 17 of the 24 previously developed override reason categories
206 **(Table 2)**. The most common reason explaining formulary deviation was the provision of a
207 ‘disease or condition’ (31.1%, n=64). No (‘blank,’ n=51) or marginal value reasons (n=30) were
208 provided in 39.4% of the alert override sample. ‘Home or Pre-Admission Medications’ reasons
209 were used to justify for 18.4% (n=38) and clinical reasons of pharmacological, specialist
210 recommendation, and failure or intolerance to formulary alternatives definition for only 11.2%
211 (n=23) of the NFM alert override sample.

212 Fischer’s exact test confirmed a disproportionate distribution of inappropriate overrides
213 among the categories of override reasons in our sample of alert overrides, $p < 0.001$. Specifically,
214 subanalysis found 55.6% (n=20) of inappropriate overrides were nested in the ‘blank’ override
215 reason category, while ‘blanks’ only accounted for 24.8% of all override reasons, $p=0.0001$.
216 Contrary, 11.1% of inappropriate overrides were nested in the ‘disease or condition’ reason
217 category, while these reasons accounted for 31.1% of the reasons in our sample, $p=0.0004$.
218 Statistical analysis did not find a disproportionate number of inappropriate overrides in the
219 remaining override reason categories **(Table 2)**.

220 Chart reviews identified 24 (66.7%) of the 36 inappropriate NFM alert overrides were
221 the result of not trialing formulary alternatives prior to the NFM **(Table 3)**. Eight (22.2%) of the
222 inappropriate NFM alert overrides were justified as a pre-admission or home medication, but
223 no evidence of active outpatient prescription was found in the patient’s LMR. Chart reviews
224 also found no or limited information justifying the use of the NFMs in three (8.3%)
225 inappropriate overrides. These overrides were overridden with a ‘blank’ or marginal value

226 reason (prescriber preference). Lastly, there was one case where the NFM was deemed
227 clinically inappropriate to the patient involving the use of an atypical antipsychotic to address
228 dementia in an elderly patient, which has been linked to adverse outcome in chronic and as-
229 needed used.^{13,14} Post-hoc analysis identified found 'blank' and marginal value reasons have the
230 highest frequency of discordant override reasons, 94.1% and 93.3%, respectively (**Table 4**).

Table 3: Reasons explaining why the NFM alert override was considered inappropriate

Non-Formulary Alert Override Reason Class	Total	Formulary alternative was not first trial prior to NFM alert override	No citation or information could be found justifying formulary deviation during chart review	Clinically Inappropriate	No evidence of active home medication found in LMR	No documentation of specialist recommendation during chart review
Blank	20	17	1	0	2	0
Disease or Condition Listed	4	4	0	0	0	0
Home or Pre-Admission Medication	5	0	0	0	5	0
Marginal Value for NF Decision: MD/Attending/Team Request, Prefers NF Medication	3	0	2	1	0	0
Marginal Value for NF Decision: Reason Listed "Need*/Requir*" OR Patient Need*/Require*	1	0	0	0	1	0
Pharmacological Reason: Drug Route Conflict	1	0	0	0	0	1
Specialist Recommendation	1	1	0	0	0	0
Therapeutic Failure / Intolerant to formulary alternatives: [Unspecified or Medication Not Listed]	1	1	0	0	0	0
Total	36	23 (63.89%)	3 (8.33%)	1 (2.78%)	8 (22.22%)	1 (2.78%)

Table 4: Frequency of Discordant NFM Alert Override Reasons

Initiate Non-Formulary Override Reason Classification	Final NFM Override Reason Category (Post-Chart Review)									
	Total	Frequency of Discordant Reason for NFM Alert Override	Blank	Disease or Condition Listed	Home or Pre-Admission Medication	Marginal Value for NF Decision: MD/Attending/Team Request, Prefers, NF Medication	Pharmacological Reason: Drug Route Conflict	Pharmacological Reason: Others	Specialist Recommendation	Therapeutic Failure / Intolerant to formulary alternatives: [Medication Listed]
Blank	51	94.1%	3	42	3	0	0	0	0	3
Disease or Condition Listed	64	7.8%	0	59	4	0	1	0	0	0
Home or Pre-Admission Medication	38	10.5%	0	1	34	0	0	0	3	0
Marginal Value for NF Decision:	30	93.3%	0	16	10	2	1	0	0	1
<i>MisCommunication: Medication use direction</i>	3	100.0%	0	2	1	0	0	0	0	0
<i>Acknowledge NF status</i>	2	100.0%	0	1	1	0	0	0	0	0
<i>Content Free</i>	1	100.0%	0	1	0	0	0	0	0	0
<i>MD/Attending/Team Request, Prefers NF Medication</i>	11	81.8%	0	7	2	2	0	0	0	0
<i>Others</i>	2	100.0%	0	2	0	0	0	0	0	0
<i>Patient Preference/Request Reason Listed</i>	2	100.0%	0	0	1	0	1	0	0	0
<i>"Appropriate, Effective, Indicated, Medical Necessity, No Alternative Reason Listed</i>	1	100.0%	0	0	0	0	0	0	0	1
<i>"Need*/Requir* OR Patient Need*/Require*</i>	8	100.0%	0	3	5	0	0	0	0	0
Pharmacological Reason:	4	50.0%	0	1	0	0	1	1	0	1
<i>Contraindication</i>	1	100.0%	0	1	0	0	0	0	0	0
<i>Drug Route Conflict</i>	1	0.0%	0	0	0	0	1	0	0	0
<i>Others</i>	2	50.0%	0	0	0	0	0	1	0	1
Specialist Recommendation: Specialist / Other Service Recommended	10	20.0%	0	2	0	0	0	0	8	0

Therapeutic Failure / Intolerant to formulary alternatives:	9	33.3%	0	1	0	0	0	0	0	8
<i>Medication Listed</i>	6	0.0%	0	0	0	0	0	0	0	6
<i>Unspecified or Medication Not Listed</i>	3	33.3%	0	1	0	0	0	0	0	2
Total	206		3	122	51	2	3	1	11	13

232

233 **Discussion**

234 Our observational study found approximately one-fifth of NFM alerts at our institution are
235 inappropriately overridden. Non-oral NFM alerts were more likely to be inappropriately
236 overridden compared to oral NFMs. We also found NFM alerts overridden with 'blank' were
237 more likely to be inappropriately overridden. Contrary, alerts overridden with 'disease or
238 condition' reasons are less likely to be inappropriately overridden. In-depth chart review found
239 the failure to trial a formulary alternative is the most common reason for a NFM alert override
240 to be inappropriate. Lastly, NFM alerts overridden with 'blank' or 'marginal value' reasons often
241 had justifiable formulary deviation reasons in the medical notes, but poorly documented in the
242 NFM alert pop-up interface.

243 To our knowledge there are no studies evaluating the appropriateness of NFM alert
244 overrides. This is likely attributed to the resource-intensive task of creating appropriateness
245 criteria for each NFM. Thus, we are unsure of how our findings compared to other institutions.
246 However, evaluating NFM alerts is inherently evaluating NFM use. Therefore, inappropriate
247 NFM usage frequencies may provide some estimation of the frequency of inappropriate NFM
248 alerts overrides.

249 Available studies suggest the frequency of inappropriate NFM usage is approximately 60%
250 to 70%. Specifically, a small 6-week prospective study at an academic medical center found 61%
251 of NFM use failed to comply to institution criteria⁸ and a study evaluating the impact of a
252 comprehensive formulary management system from a no structured system decreased NFM
253 utilization from 17.8 to 5.9 medications per 100 admissions. This suggests an upper 67% bound

254 of inappropriate NFM use.² Our lower frequency is likely attributed to BWH's 'relaxed'
255 formulary and our sample was composed of NFMs previously approved by pharmacist for use,
256 hence also decreasing the number of inappropriate alert overrides.

257 The literature on formulary CDS is scarce. Our secondary findings provide important
258 perspective on the better design of these informatic tools for automated formulary
259 management. First, improvement in NFM alert systems should be prioritized to focus on non-
260 oral NFMs. Non-oral NFMs have greater formulary cost-implications than oral NFMs. Sweet et
261 al estimated the successful conversion of non-oral NFMs to a formulary alternative saves \$7.04
262 to \$94.60 compared to \$16.62 in oral NFMs.⁴ Our study found non-oral NFM alert overrides
263 more likely to be inappropriate compared to oral NFMs. Thus, optimization of automated
264 formulary management with non-oral NFMs is more likely to ensure formulary cost-savings.

265 Second, it is not surprising that the provision of no reason ('blank') to NFM alerts overrides
266 were disproportionately inappropriate. This is likely reflective of BWH's 'relaxed' formulary, but
267 also a characteristics volunteer free-texted alert system.¹⁶ Mandating the provision of an
268 override reason may decrease the frequency of inappropriate NFM alert overrides.

269 Third, we expected NFM alerts overridden with clinical reasons (pharmacological, specialist
270 recommendation, and therapeutic failure / intolerant to formulary alternatives) to be more
271 likely appropriate, but was only able to demonstrate this relationship with alerts overridden
272 with 'disease or condition' reasons. The inability to demonstrate this hypothesis with the
273 former clinical reasons is likely due to their small numbers in our sample. Our previous study
274 found clinical reasons were rarely entered into our alert system (*cite AJHP study*), which is

275 surprising with our sampling being composed of only approved NFM overrides. Chart review
276 found nearly all ‘blank’ (45 of the 51) and ‘marginal value’ (28 of the 30) reasons were of clinical
277 reasons and potentially appropriate in our post-hoc analysis (**Table 4**). Thus, mandating the
278 provision of any override reason is likely to increase the frequency of alerts overridden with
279 clinical reasons, inherently decreasing the frequency of inappropriate NFM alert overrides.

280 Fourth, chart review found inappropriate NFM alert overrides were largely attributed to
281 prescriber not trialing formulary alternatives prior to the NFM. This is likely due to BWH’s large
282 number of NFMs managed by a soft stop, where guidance to formulary alternatives is not
283 provided. Listing formulary alternatives in the pop-up alerts is likely to facilitate the use and
284 trial of formulary alternatives, hence decreasing the frequency of inappropriate NFM alert
285 overrides. A recent study found an obtrusive, hard-stop, pop-up alert prompting formulary
286 interchange decreased non-formulary non-adherence by 65%.¹⁷ In addition a list of formulary
287 alternatives that is clear, concise, and include links to additional information may further
288 decrease the frequency of inappropriate NFM alert overrides.^{11,18-20}

289 *Limitations*

290 Our study has a number of limitations. First, our study was retrospective and we limited
291 our review to the information documented in the inpatient medical notes. There were three
292 ‘blank’ overrides where no citation or information regarding the rationale of NFM use was
293 found in the inpatient notes. Contrary, there were numerous incidences where ‘blank’
294 overrides were actually justified after chart review. This leads us to infer that potentially

295 prescribers could have discussed the rationale for NFM use with the team, specialist, or
296 rounding pharmacist, but failed to document appropriately in the NFM alert pop-up window.

297 Second, our study was undertaken at a single medical center with an in-house
298 developed COPE system and utilized appropriateness criteria specific to one institution. Thus
299 the results may not be fully generalizable to other institutions and medication ordering system.
300 Nevertheless, our findings provide important perspective on the design of computerized
301 formulary management systems and formulary-based CDS, which may further ensure formulary
302 cost-savings, quality of care, and medication safety. In addition, our study empirically applied a
303 previously developed general appropriateness criteria; thus the presented study may serve as a
304 model for future formulary-based CDS studies and generate more override appropriateness
305 evaluation.

306 Lastly, our analysis focused on only a subset of NFM alert overrides, the most approved
307 and highest costing NFMs. Thus, it remains unknown how our findings might have differ with
308 the inclusion of all NFMs. Yet such study is likely infeasible due to the need to create
309 appropriateness criteria for all NFMs. Our reasonable decision to focus on the highest cost and
310 most approved NFMs was to identify insight that may yield the greatest improvement in the
311 use of alerts for formulary management.

312 **Conclusion**

313 To our knowledge, our study is the first to empirically evaluate the appropriateness of
314 NFM alerts overrides in the inpatient setting. Evaluating the effectiveness of these overrides is
315 inherently evaluating NFM usage. This is a labor-intensive task and requires the creation of

316 appropriateness criteria for each NFM. We circumvented this issue by tailoring an empirically
317 developed NFM alert override general appropriateness algorithm to our institution's NFM
318 policy and use criteria and focused on the most approved and high costing NFMs. The present
319 study conservatively estimates that one in five NFM alert overrides is inappropriately
320 overridden and at minimum mandating an override reason for each NFM alert override and
321 adding a list of formulary alternatives to each NFM alert may decrease the frequency of
322 inappropriate NFM alert overrides.

323 ***This study was funded by grant #U19HS021094 from the Agency for Healthcare Research and***
324 ***Quality (AHRQ).***

325 ***Dr. Beeler was supported by the Swiss National Science Foundation.***

326 **Reference**

- 327 1. Tyler LS, Cole SW, May JR, et al. ASHP guidelines on the pharmacy and therapeutics committee
328 and the formulary system. *Am J Health Syst Pharm* 2008;65:1272-83.
- 329 2. Helmons PJ, Kosterink JG, Daniels CE. Formulary compliance and pharmacy labor costs
330 associated with systematic formulary management strategy. *Am J Health Syst Pharm* 2014;71:407-15.
- 331 3. Pantaleo N, Wu WK, Talan M. The evaluation of nonformulary prescribing in a community
332 teaching hospital. *P T* 2000;25:25-38.
- 333 4. Sweet BV, Stevenson JG. Pharmacy costs associated with nonformulary drug requests. *Am J*
334 *Health Syst Pharm* 2001;58:1746-52.
- 335 5. Cohen MR. ISMP Medication Error Report Analysis. *Hosp Pharm* 2006;41:811-5, 902.
- 336 6. Cohen MR, Smetzer JL. ISMP Medication Error Report Analysis. *Hosp Pharm* 2011;46:238-9, 46.
- 337 7. Cohen MR, Smetzer JL. ISMP Medication Error Report Analysis. *Hosp Pharm* 2012;47:328-31.
- 338 8. Pummer TL, Shalaby KM, Erush SC. Ordering off the menu: assessing compliance with a
339 nonformulary medication policy. *Ann Pharmacother* 2009;43:1251-7.
- 340 9. Kuperman GJ, Bobb A, Payne TH, et al. Medication-related clinical decision support in
341 computerized provider order entry systems: a review. *J Am Med Inform Assoc* 2007;14:29-40.
- 342 10. Schedlbauer A, Prasad V, Mulvaney C, et al. What evidence supports the use of computerized
343 alerts and prompts to improve clinicians' prescribing behavior? *J Am Med Inform Assoc* 2009;16:531-8.
- 344 11. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized
345 physician order entry. *J Am Med Inform Assoc* 2006;13:138-47.
- 346 12. Teich JM, Glaser JP, Beckley RF, et al. The Brigham integrated computing system (BICS):
347 advanced clinical systems in an academic hospital environment. *Int J Med Inform* 1999;54:197-208.
- 348 13. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use
349 in older adults. *J Am Geriatr Soc* 2012;60:616-31.
- 350 14. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for
351 dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005;294:1934-43.
- 352 15. Plet HT, Hallas J, Kjeldsen LJ. Adherence to hospital drug formularies and cost of drugs in
353 hospitals in Denmark. *Eur J Clin Pharmacol* 2013;69:1837-43.
- 354 16. Chused AE, Kuperman GJ, Stetson PD. Alert override reasons: a failure to communicate. *AMIA*
355 *Annu Symp Proc* 2008:111-5.
- 356 17. Helmons PJ, Coates CR, Kosterink JG, Daniels CE. Decision support at the point of prescribing to
357 increase formulary adherence. *Am J Health Syst Pharm* 2015;72:408-13.
- 358 18. Feldstein A, Simon SR, Schneider J, et al. How to design computerized alerts to safe prescribing
359 practices. *Jt Comm J Qual Saf* 2004;30:602-13.
- 360 19. Sittig DF, Krall MA, Dykstra RH, Russell A, Chin HL. A survey of factors affecting clinician
361 acceptance of clinical decision support. *BMC Med Inform Decis Mak* 2006;6:6.
- 362 20. Horsky J, Schiff GD, Johnston D, Mercincavage L, Bell D, Middleton B. Interface design principles
363 for usable decision support: a targeted review of best practices for clinical prescribing interventions. *J*
364 *Biomed Inform* 2012;45:1202-16.

365

366